If a gene mutation is found and there is a drug that is expected to be effective against
the gene mutation, the use of the drug will be examined in clinical trials and the like.
Preparations are underway from 2019 onward for oncology panel testing to be
received in insurance practice.
For example, if there is a specific gene mutation, the analysis result is considered
by a committee composed of multiple experts. The doctor will use this as a reference
for diagnosis and treatment to see if there is a drug that is expected to be effective for
gene mutation. If such a drug exists, consider using that drug, including in clinical
trials. If there is no such drug, other treatments will be considered. It is not easy to
clear the requirements for the implementation of the cancer genomic medicine that
presupposes the oncogenic panel test. The following are the major conditions that
must be satisfied.
1. There is a system that can carry out panel inspections, including cooperation with
external organizations.
2. There is an interprofessional collaboration team to medically interpret the panel
test results.
3. Specialized genetic counseling is possible for patients with hereditary tumors.
4. There are more than a certain number of cases for subjects such as panel
examinations.
5. It is possible to collect and manage panel test results and clinical information in an
appropriate way with security. In addition, necessary information can be registered at the Cancer Genome Information Management Center.
6. There is a system that allows fresh frozen preservation of surgical specimens, etc.
7. There is an appropriate interprofessional collaboration team to conduct advanced
medicine and physician-led clinical trials, including international joint clinical
trials.
8. There is an easy-to-understand window for patients to use medical information
and provide clinical trial information.
With the advent of increasingly sophisticated sequencers, however, genomic
mutations are being discovered one after another (hundreds to millions). When
looking at the flow of genomic medicine and personalization of medicine in cancer,
the researcher’s interpretation and translation become a bottleneck (Good et al.,
2014).
6 Cognitive Technology and Augmented Intelligence
By the year 2016, 26 million articles have been registered on PubMed (Medical and
Biological Articles Abstracts Database) of the U.S. National Institute of Health.
When printed, its thickness is as much as 4000 m, far exceeding the height of
Mt. Fuji. As of 2016, the number of articles on cancer alone exceeded 200,000.
Since then, the number of papers has been increasing exponentially, and it will reach
a height of 100 km, beyond the atmospheric layer, in 2050 (Miyano, 2018).
Innovation in Health Informatics
19
the gene mutation, the use of the drug will be examined in clinical trials and the like.
Preparations are underway from 2019 onward for oncology panel testing to be
received in insurance practice.
For example, if there is a specific gene mutation, the analysis result is considered
by a committee composed of multiple experts. The doctor will use this as a reference
for diagnosis and treatment to see if there is a drug that is expected to be effective for
gene mutation. If such a drug exists, consider using that drug, including in clinical
trials. If there is no such drug, other treatments will be considered. It is not easy to
clear the requirements for the implementation of the cancer genomic medicine that
presupposes the oncogenic panel test. The following are the major conditions that
must be satisfied.
1. There is a system that can carry out panel inspections, including cooperation with
external organizations.
2. There is an interprofessional collaboration team to medically interpret the panel
test results.
3. Specialized genetic counseling is possible for patients with hereditary tumors.
4. There are more than a certain number of cases for subjects such as panel
examinations.
5. It is possible to collect and manage panel test results and clinical information in an
appropriate way with security. In addition, necessary information can be registered at the Cancer Genome Information Management Center.
6. There is a system that allows fresh frozen preservation of surgical specimens, etc.
7. There is an appropriate interprofessional collaboration team to conduct advanced
medicine and physician-led clinical trials, including international joint clinical
trials.
8. There is an easy-to-understand window for patients to use medical information
and provide clinical trial information.
With the advent of increasingly sophisticated sequencers, however, genomic
mutations are being discovered one after another (hundreds to millions). When
looking at the flow of genomic medicine and personalization of medicine in cancer,
the researcher’s interpretation and translation become a bottleneck (Good et al.,
2014).
6 Cognitive Technology and Augmented Intelligence
By the year 2016, 26 million articles have been registered on PubMed (Medical and
Biological Articles Abstracts Database) of the U.S. National Institute of Health.
When printed, its thickness is as much as 4000 m, far exceeding the height of
Mt. Fuji. As of 2016, the number of articles on cancer alone exceeded 200,000.
Since then, the number of papers has been increasing exponentially, and it will reach
a height of 100 km, beyond the atmospheric layer, in 2050 (Miyano, 2018).
Innovation in Health Informatics
19